mocetinostat
Sign in to saveAlso known as MGCD0103
Mocetinostat (MGCD0103) is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers including follicular lymphoma, Hodgkin's lymphoma and acute myelogenous leukemia.
Research
151 papers- Mocetinostat activates Krüppel-like factor 4 and protects against tissue destruction and inflammation in osteoarthritis.JCI insight · 2023
- Mocetinostat (MGCD0103): a review of an isotype-specific histone deacetylase inhibitor.Expert opinion on investigational drugs · 2011
- Mocetinostat suppresses epidural fibrosis following laminectomy by inhibiting myofibroblast activation and increasing apoptosis.European review for medical and pharmacological sciences · 2020
- Mocetinostat in Combination With Durvalumab for Patients With Advanced NSCLC: Results From a Phase I/II Study.Clinical lung cancer · 2023
- Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes.Cancer · 2019
via PubMed
~1 min read
Encyclopedic overview
2 sectionsContents
- Mechanism of action
- References
{{chembox | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 444509574 | ImageFile = mocetinostat.png | ImageClass = skin-invert-image | ImageSize = 200px | PIN = N-(2-Aminophenyl)-4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzamide | OtherNames = |Section1= |Section2= |Section3= }}
Mocetinostat (MGCD0103) is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers including follicular lymphoma, Hodgkin's lymphoma and acute myelogenous leukemia.
Excerpted from Wikipedia’s “mocetinostat” article, available under the CC BY-SA 4.0 licence.